NEW YORK and LA JOLLA, Calif., May 29, 2019 /PRNewswire/ -- Constellation Alpha Capital Corp. (CNAC) ("Constellation"), a special purpose acquisition company, announced that it has executed a definitive agreement to merge with DermTech, Inc. ("DermTech"), a molecular genomics company, with an initial focus on skin cancer, that develops and markets novel non-invasive diagnostic tests. DermTech is a leading genomics company in dermatology, bringing precision medicine to the diagnosis and treatment of skin disease.  DermTech markets and develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and help customize drug treatment.